Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Stress CT Perfusion in Patients With Chest Pain

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by University of Chicago
Astellas Pharma Inc
Information provided by (Responsible Party):
University of Chicago Identifier:
First received: October 21, 2013
Last updated: May 11, 2016
Last verified: May 2016

Our hypothesis is that quantitative 3D analysis of cardiac CT images obtained during vasodilator stress can accurately identify patients presenting at the emergency department with acute chest pain due to underlying hemodynamically significant coronary stenosis, aid in the identification of individuals most likely to benefit from revascularization, and thus improve the ability to predict patient outcomes.

Our goals are:

  1. to test the above hypothesis by comparing stress MDCT perfusion data with invasive fractional flow reserve (FFR) data in patients with significant stenosis who undergo ICA;
  2. to determine the added value of MDCT perfusion as an adjunct to CTCA for predicting patient outcomes.

Condition Intervention
Coronary Artery Disease
Drug: Regadenoson

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Comprehensive Evaluation of Patients With Chest Pain Using Cardiac Computed Tomography: Value of Adding Regadenoson Stress Perfusion Imaging to Noninvasive Coronary Angiography

Resource links provided by NLM:

Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • Ability to detect stress-induced perfusion abnormalities by 3D analysis of MDCT images [ Time Frame: 6 months ]

Estimated Enrollment: 300
Study Start Date: June 2014
Estimated Study Completion Date: June 2019
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Regadenoson Drug: Regadenoson
Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
Other Name: Lexiscan

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with acute chest pain referred by the emergency department for CT coronary angiography

Exclusion Criteria:

  • allergy to iodine,
  • renal dysfunction (creatinine >1.6 mg/dL)
  • chronic obstructive pulmonary disease
  • advanced heart block
  • or systolic blood pressure <90 mmHg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01969916

Contact: Victor Mor-Avi, Ph.D. 773-702-7780
Contact: Amit R. Patel, M.D. 773-834-3363

United States, Illinois
University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Victor Mor-Avi   
Principal Investigator: Amit R. Patel, M.D.         
Sponsors and Collaborators
University of Chicago
Astellas Pharma Inc
Principal Investigator: Victor Mor-Avi, Ph.D. University of Chicago
  More Information


Responsible Party: University of Chicago Identifier: NCT01969916     History of Changes
Other Study ID Numbers: 15237B-AM005
Study First Received: October 21, 2013
Last Updated: May 11, 2016

Keywords provided by University of Chicago:
Cardiac CT imaging
Myocardial ischemia
Myocardial perfusion
Vasodilator stress testing

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Chest Pain
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Adenosine A2 Receptor Agonists
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on April 26, 2017